文献速递关节外科小儿骨科创伤骨科

股骨转子下短缩截骨在单侧Crowe IV型发育性髋关节发育不良全髋关节置换中较转子滑移截骨提供更优功能:至少3年随访

Subtrochanteric Shortening Osteotomy Provides Superior Function to Trochanter Slide Osteotomy in THA for Patients With Unilateral Crowe Type IV Dysplasia at a Minimum of 3 Years.
PubMed 文献 · Clin Orthop Relat Res · 2023-10-27

这项回顾性比较研究纳入单侧Crowe IV型发育性髋关节发育不良行全髋关节置换的患者,按性别和术前Harris髋关节评分匹配后比较股骨转子下短缩截骨与转子滑移截骨的疗效。至少3年随访时,转子下短缩截骨组Harris髋关节评分改善更大,骨不连风险更低,下肢不等长矫正更优。

要点

  • 转子下短缩截骨组Harris髋关节评分改善48±4分,优于转子滑移截骨组的36±11分。
  • 转子滑移截骨组骨不连发生率为23%(5/22),转子下短缩截骨组为0%(0/22)。
  • 转子下短缩截骨组术后下肢不等长改善44±8 mm,优于转子滑移截骨组的38±8 mm。

核心结论

  • 在行全髋关节置换的Crowe IV型髋关节发育不良患者中,作者认为术者可考虑股骨转子下短缩截骨而非转子滑移截骨,以降低骨不连风险并获得更优髋关节功能。
  • 股骨转子下短缩截骨可能实现更好的下肢不等长矫正。
  • 两种技术术后髋关节的长期生存率以及股骨近端特定解剖对技术选择的影响,仍有待未来研究探索。

研究设计与样本

  • 回顾性比较研究,比较股骨转子下短缩截骨与转子滑移截骨两组,按性别和术前Harris髋关节评分匹配,随访至少3年。
  • 2010年至2018年间共对单侧Crowe IV型发育性髋关节发育不良患者实施67例全髋关节置换。
  • 当时常规对所有Crowe IV型患者采用转子滑移截骨,当无锥形柄可用时行股骨转子下短缩截骨。
  • 67例中42%(28例)行股骨转子下短缩截骨,58%(39例)行转子滑移截骨;两组分别有89%(25例)和74%(29例)具备至少3年随访的完整数据集可供匹配。
  • 按性别和术前Harris髋关节评分(差值在10分以内)匹配后,每组各22例进入评估分析(转子下短缩截骨组占79%,转子滑移截骨组占56%)。

主要发现

  • 两组年龄(42岁 vs 46岁)、性别(女性:73% vs 73%)、术前Harris髋关节评分(40分 vs 40分)和术前下肢不等长(5.9 cm vs 5.3 cm)具有可比性(p > 0.05)。
  • 转子滑移截骨组全部使用Cone Wagner(Zimmer)假体(100%),转子下短缩截骨组最常用Corail(DePuy Synthes)假体(77%)。
  • 平均随访73个月时,转子下短缩截骨组Harris髋关节评分改善大于转子滑移截骨组(48±4分 vs 36±11分,平均差值12分[95%CI 7至17分];p < 0.001)。
  • 两组术前下肢不等长相似,但转子下短缩截骨组术后改善更大(转子下短缩截骨组44±8 mm vs 转子滑移截骨组38±8 mm;p = 0.02)。
  • 转子滑移截骨组骨不连风险高于转子下短缩截骨组(23%[5/22] vs 0%[0/22];p = 0.048)。

临床怎么用

  • 作者认为,在行全髋关节置换的Crowe IV型髋关节发育不良患者中,术者可考虑股骨转子下短缩截骨而非转子滑移截骨,以降低骨不连风险并获得更优髋关节功能。
  • 作者认为,股骨转子下短缩截骨可能实现更好的下肢不等长矫正。

局限性

  • 两种技术术后髋关节的长期生存率以及股骨近端特定解剖对技术选择的影响,仍有待未来研究探索。
  • 证据等级为III级,治疗性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Performing THA in patients with high-riding developmental dysplasia of the hip (DDH) is associated with serious complications and technical challenges. Various methods of shortening osteotomy are available to facilitate femoral head reduction during THA in patients with high-riding hips; subtrochanteric shortening osteotomy and trochanteric slide osteotomy plus proximal shortening are the most common techniques. However, which approach is superior remains a topic of controversy. QUESTIONS/PURPOSES: (1) Is there any difference in clinical outcomes (defined as the Harris Hip Score [HHS] and residual limb length discrepancy) at a minimum of 3 years between subtrochanteric shortening osteotomy and trochanteric slide osteotomy in patients with Crowe Type IV DDH who underwent THA? (2) Is there any difference in the risk or type of complications between the two approaches? METHODS: We performed a retrospective, comparative study of two groups (subtrochanteric shortening osteotomy versus trochanteric slide osteotomy) matched for sex and preoperative HHS at a minimum of 3 years of follow-up. Between 2010 and 2018, we performed 67 THAs in patients with unilateral Crowe Type IV DDH. During that time, we generally used a trochanteric slide osteotomy for THA in all patients with Crowe Type IV hips and performed subtrochanteric shortening osteotomy when a conical stem was not available. A total of 42% (28) had THA with subtrochanteric shortening osteotomy, and 58% (39) had THA with trochanteric slide osteotomy. Of those, 89% (25) and 74% (29), respectively, were accounted for with complete datasets for possible matching at a minimum of 3 years of follow-up. Patients were matched for gender and preoperative HSS (within 10 points), leaving 22 patients in each group (79% of the subtrochanteric shortening osteotomy group and 56% of the trochanteric slide osteotomy group) for evaluation and analysis. Age (42 versus 46 years), gender (female: 73% versus 73%), preoperative HSS (40 versus 40), and preoperative leg length discrepancy (5.9 versus 5.3 cm) were comparable between the two groups (p > 0.05). The trochanteric slide osteotomy group exclusively received Cone Wagner (Zimmer) implants (100%), while Corail (DePuy Synthes) implants (77%) were the most commonly used in the subtrochanteric shortening osteotomy group. HHS at a minimum of 3 years as well as the presence or absence of a limp and Trendelenburg sign, functional leg length discrepancy, nonunion, nerve palsy, and other surgical complications were recorded and compared between the groups based on data drawn from a longitudinally maintained institutional database. RESULTS: At a mean follow-up of 73 months, improvement in HHS was greater in the subtrochanteric shortening osteotomy group than in the trochanteric slide osteotomy group (48 ± 4 points versus 36 ± 11 points, mean difference 12 points [95% CI 7 to 17 points]; p < 0.001). Although the preoperative leg length discrepancy was similar between the groups, there was a greater postoperative improvement in the subtrochanteric shortening osteotomy group (44 ± 8 mm and 38 ± 8 mm in the subtrochanteric shortening osteotomy and trochanteric slide osteotomy groups, respectively; p = 0.02). The risk of nonunion was higher with a trochanteric slide osteotomy than with a subtrochanteric shortening osteotomy (23% [5 of 22] versus 0% [0 of 22]; p = 0.048). Other complications, including intraoperative periprosthetic fractures, nerve palsy, heterotopic ossification, revision surgery, and dislocation, did not differ between the groups. CONCLUSION: In patients with Crowe Type IV hips undergoing THA, surgeons might consider subtrochanteric shortening osteotomy rather than trochanteric slide osteotomy to minimize the risk of nonunion and achieve superior hip function. Better correction of leg length discrepancy may also be possible with subtrochanteric shortening osteotomy. The long-term survivorship of hips after these two techniques, as well as the influence of the specific anatomy of the proximal femur on the choice of technique, remain to be explored in future studies. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Ravanbod H, Gharanizadeh K, Mirghaderi P, et al. Subtrochanteric Shortening Osteotomy Provides Superior Function to Trochanter Slide Osteotomy in THA for Patients With Unilateral Crowe Type IV Dysplasia at a Minimum of 3 Years. Clin Orthop Relat Res. 2023. PMID: 37889537. doi:10.1097/CORR.0000000000002900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。